| Title: |
“Are new lipid lowering agents a good option for achieving lipid goals in people living with HIV? A case report” |
| Authors: |
Ferri, Raffaele; Falasca, Katia; Vecchiet, Jacopo; Ucciferri, Claudio |
| Contributors: |
Ferri, Raffaele; Falasca, Katia; Vecchiet, Jacopo; Ucciferri, Claudio |
| Publication Year: |
2025 |
| Collection: |
IRIS Università degli Studi di Perugia |
| Subject Terms: |
Bempedoic acid; inclisiran; statins; dyslipidemia |
| Description: |
The dyslipidemia in people living with HIV differs from the general population because combination antiretroviral therapy may not only induce dyslipidemia but also interact with lipid-lowering agents. Monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) have recently been demonstrated to dramatically reduce LDL-C level (>60%) in the majority of cases, and another interesting new option is inclisiran, a firstin-class, cholesterol-lowering small interfering RNA (siRNA) targeting PCSK9 mRNA and conjugated to triantennary Nacetylgalactosamine carbohydrates (GalNAc). We present the clinical case of a 62-year-old man living with HIV and dyslipidemia in whom new hypolipidemic drugs were fundamental in achieving adequate LDL values to prevent cardiovascular events. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40123063; info:eu-repo/semantics/altIdentifier/wos/WOS:001450515000001; volume:0; issue:0; firstpage:1; lastpage:4; numberofpages:4; journal:INTERNATIONAL JOURNAL OF STD & AIDS; https://hdl.handle.net/11391/1611755 |
| DOI: |
10.1177/09564624251327237 |
| Availability: |
https://hdl.handle.net/11391/1611755; https://doi.org/10.1177/09564624251327237; https://journals.sagepub.com/doi/10.1177/09564624251327237 |
| Accession Number: |
edsbas.886DF916 |
| Database: |
BASE |